Lewis Kevin Michael, Kuntze Carl Erik, Gulle Heinz
Preclinical Safety and Efficacy, Baxter Healthcare Corporation, Deerfield, IL, USA.
Medical Affairs, Baxter Healthcare SA, Zurich, Switzerland.
Med Devices (Auckl). 2015 Dec 22;9:1-10. doi: 10.2147/MDER.S90591. eCollection 2016.
The need for advanced hemostatic agents increases with the complexity of surgical procedures and use of anticoagulation and antiplatelet treatments. HEMOPATCH (Sealing Hemostat) is a novel, advanced hemostatic pad that is composed of a synthetic, protein-reactive monomer and a collagen backing. The active side is covered with a protein-reactive monomer: N-hydroxysuccinimide functionalized polyethylene glycol (NHS-PEG). NHS-PEG rapidly affixes the collagen pad to tissue to promote and maintain hemostasis. The combined action of the NHS-PEG and collagen is demonstrated to have benefit relative to other hemostatic agents in surgery and preclinical surgical models. This paper reviews the published investigations and case reports of the hemostatic efficacy of HEMOPATCH, wherein HEMOPATCH is demonstrated to be an effective, easy-to-use hemostatic agent in open and minimally invasive surgery of patients with thrombin- or platelet-induced coagulopathies.
随着外科手术复杂性的增加以及抗凝和抗血小板治疗的使用，对先进止血剂的需求也在增加。HEMOPATCH（密封止血剂）是一种新型的先进止血垫，由合成的蛋白质反应性单体和胶原蛋白背衬组成。活性面覆盖有蛋白质反应性单体：N-羟基琥珀酰亚胺功能化聚乙二醇（NHS-PEG）。NHS-PEG能迅速将胶原蛋白垫固定在组织上，以促进和维持止血。在手术和临床前手术模型中，NHS-PEG和胶原蛋白的联合作用已被证明相对于其他止血剂具有优势。本文回顾了已发表的关于HEMOPATCH止血效果的研究和病例报告，其中HEMOPATCH被证明是一种在患有凝血酶或血小板诱导性凝血病的患者的开放手术和微创手术中有效且易于使用的止血剂。
